Patents by Inventor Joachim Moecks
Joachim Moecks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150111211Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
-
Patent number: 8940302Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.Type: GrantFiled: October 9, 2012Date of Patent: January 27, 2015Assignees: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
-
Publication number: 20110246399Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.Type: ApplicationFiled: June 1, 2011Publication date: October 6, 2011Applicants: Genentech, Inc., Hoffmann-La Roche, Inc.Inventors: LUKAS C. AMLER, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
-
Publication number: 20110245103Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.Type: ApplicationFiled: June 1, 2011Publication date: October 6, 2011Applicants: Genentech, Inc., Hoffmann-La Roche. Inc.Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
-
Patent number: 7981418Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.Type: GrantFiled: March 1, 2008Date of Patent: July 19, 2011Assignees: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
-
Publication number: 20100279431Abstract: The present invention relates to diagnosing the risk of developing a need for dialysis and/or predicting a need for dialysis, particularly in patients suffering from renal disorders, comprising the steps of measuring the level of a BNP-type peptide or a variant thereof in a sample from the patient, diagnosing the risk by comparing the measured level of the BNP-type peptide or a variant thereof to at least one reference level. The BNP-type peptide may, for example, be brain natriuretic peptide (BNP), proBNP, NT-proBNP, a variant of BNP, a variant of proBNP, or a variant of NT-proBNP.Type: ApplicationFiled: February 29, 2008Publication date: November 4, 2010Inventors: Ildiko Amann-Zalan, Joachim Moecks, Hans Ulrich Burger, Cesar Escrig, Armin Scherhag, Frank Dougherty, Zuzana Herrmann
-
Publication number: 20100196931Abstract: The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.Type: ApplicationFiled: November 19, 2009Publication date: August 5, 2010Inventors: Ulrich Brennscheidt, Otmar Herrgott, Astrid Heller, Verena Lutz, Joachim Moecks, Carol Ward
-
Publication number: 20100112603Abstract: The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.Type: ApplicationFiled: November 24, 2009Publication date: May 6, 2010Inventors: Joachim Moecks, Andreas Strauss, Gerhard Zugmaier
-
Patent number: 7700299Abstract: The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.Type: GrantFiled: May 19, 2006Date of Patent: April 20, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Joachim Moecks, Andreas Strauss, Gerhard Zugmaier
-
Patent number: 7655414Abstract: The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.Type: GrantFiled: May 10, 2006Date of Patent: February 2, 2010Assignee: Hoffman La-Roche Inc.Inventors: Ulrich Brennscheidt, Otmar Herrgott, legal representative, Astrid Heller, Verena Lutz, Joachim Moecks, Carol Ward
-
Publication number: 20100008975Abstract: The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also describes the use of high HER2:HER3 ratio as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a HER inhibitor, such as pertuzumab. In addition, the application describes the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, for instance gemcitabine.Type: ApplicationFiled: March 1, 2008Publication date: January 14, 2010Inventors: Lukas C. Amler, Merrill Birkner, Chin-Yu Lin, Joachim Moecks, Andreas Strauss
-
Publication number: 20080050749Abstract: The present invention relates to the diagnosis of the risk of experiencing a cardiovascular complication in the context of treatment with erythropoiesis stimulating agents (ESA's) such as erythropoietin and derivatives thereof particularly in the context of anemia. More particularly, the invention provides a method for diagnosing the risk of a patient of experiencing a cardiovascular complication as a consequence of future medication with an erythropoiesis stimulating agent (ESA), comprising the steps of (a) measuring the level of a BNP-type peptide in a sample of the patient, (b) diagnosing said risk by comparing the measured level of the BNP-type peptide to at least one reference level. The BNP-type peptide may for example be brain natriuretic peptide (BNP) or the N-terminal fragment of BNP, NT-proBNP. The cardiovascular complication may include complications, such as stroke, transient cerebral ischemic attack, acute-coronary syndrome, myocardial infarction, congestive heart failure etc.Type: ApplicationFiled: August 17, 2006Publication date: February 28, 2008Inventors: Ildiko Amann-Zalan, Joachim Moecks, Hans Ulrich Burger, Cesar Escrig, Armin Scherhag, Frank Dougherty
-
Publication number: 20080038271Abstract: The present application describes extending survival in a cancer patient, where the patient is producing an elevated level of EGF or TGF-alpha, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.Type: ApplicationFiled: May 31, 2007Publication date: February 14, 2008Inventors: Lukas Amler, Joachim Moecks, Nusrat Rabbee, Andreas Strauss
-
Publication number: 20080036999Abstract: A method is described for the spectroscopic examination of samples which are taken from human tissue or body fluids, in particular blood, comprising the following steps: measuring an infrared spectrum of a sample to be examined; analysing the measured infrared spectrum in order to determine at least one sample parameter that characterizes the infrared spectrum in at least one of the following wavenumber ranges 2850 cm?1 to 2886 cm?1, 2798 cm?1 to 2835 cm?1, 1723 cm?1 to 1733 cm?1, 1429 cm?1 to 1465 cm?1, 1338 cm?1 to 1364 cm?1, 1089 cm?1 to 1123 cm?1, 1034 cm?1 to 1074 cm?1, comparing the at least one sample parameter with at least one reference parameter that was obtained by analysing at least one reference spectrum that was measured on at least one sample of body fluid from patients afflicted by Alzheimer's, and assigning the sample to a class with an increased suspicion of Alzheimer's disease if the deviation of the at least one sample parameter from the at least one reference parameter does not exceed a pType: ApplicationFiled: June 14, 2007Publication date: February 14, 2008Inventors: Wolfgang Petrich, Joachim Moecks
-
Publication number: 20070054330Abstract: The present invention relates to a method of determining whether a biological sample comprising human lung cancer cells is sensitive to a combination of an epidermal growth factor receptor inhibitor and a chemotherapeutic agent by determining the overexpression of a phosphorylated AKT protein and/or a phosphorylated MAPK protein in the biological sample. The invention is also related to methods for deriving a candidate agent or for selecting a composition for inhibiting the progression of lung cancer in a patient wherein a phosphorylated AKT protein and/or a phosphorylated MAPK protein is used.Type: ApplicationFiled: May 10, 2006Publication date: March 8, 2007Inventors: Ulrich Brennscheidt, Otmar Herrgott, Astrid Heller, Verena Lutz, Joachim Moecks, Carol Ward
-
Publication number: 20070037228Abstract: The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.Type: ApplicationFiled: May 19, 2006Publication date: February 15, 2007Inventors: Joachim Moecks, Andreas Strauss, Gerhard Zugmaier